S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Checking in with 5 Bitcoin Stocks Ahead of Bitcoin's Halving
Closing prices for crude oil, gold and other commodities
Lululemon’s P/E Is Back to 2017 Levels: Should You Buy the Dip?
Stock market today: Wall Street dips to send S&P 500 to its longest losing streak since January
Abbott Laboratories Outlook is Healthy: Buy the Dip
Prologis Stock Leading U.S. Logistics Boom
S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Checking in with 5 Bitcoin Stocks Ahead of Bitcoin's Halving
Closing prices for crude oil, gold and other commodities
Lululemon’s P/E Is Back to 2017 Levels: Should You Buy the Dip?
Stock market today: Wall Street dips to send S&P 500 to its longest losing streak since January
Abbott Laboratories Outlook is Healthy: Buy the Dip
Prologis Stock Leading U.S. Logistics Boom
S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Checking in with 5 Bitcoin Stocks Ahead of Bitcoin's Halving
Closing prices for crude oil, gold and other commodities
Lululemon’s P/E Is Back to 2017 Levels: Should You Buy the Dip?
Stock market today: Wall Street dips to send S&P 500 to its longest losing streak since January
Abbott Laboratories Outlook is Healthy: Buy the Dip
Prologis Stock Leading U.S. Logistics Boom
S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Checking in with 5 Bitcoin Stocks Ahead of Bitcoin's Halving
Closing prices for crude oil, gold and other commodities
Lululemon’s P/E Is Back to 2017 Levels: Should You Buy the Dip?
Stock market today: Wall Street dips to send S&P 500 to its longest losing streak since January
Abbott Laboratories Outlook is Healthy: Buy the Dip
Prologis Stock Leading U.S. Logistics Boom

Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Accelerate Diagnostics, Inc. stock logo
AXDX
Accelerate Diagnostics
$0.74
-9.8%
$1.01
$0.73
$11.90
$15.95M0.52120,477 shs122,910 shs
HORIBA, Ltd. stock logo
HRIBF
HORIBA
$98.40
+4.7%
$91.90
$51.03
$100.67
N/A0.31N/A3,400 shs
Pacific Biosciences of California, Inc. stock logo
PACB
Pacific Biosciences of California
$1.40
$4.36
$1.25
$14.55
$375.13M1.839.63 million shs35.34 million shs
Quanterix Co. stock logo
QTRX
Quanterix
$15.75
-1.2%
$24.00
$11.39
$29.70
$599.45M1.3345,886 shs481,085 shs
Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Accelerate Diagnostics, Inc. stock logo
AXDX
Accelerate Diagnostics
-6.75%-5.13%-14.12%-62.14%-89.12%
HORIBA, Ltd. stock logo
HRIBF
HORIBA
0.00%0.00%0.00%+39.15%+66.16%
Pacific Biosciences of California, Inc. stock logo
PACB
Pacific Biosciences of California
-50.62%-61.22%-63.06%-77.09%-87.28%
Quanterix Co. stock logo
QTRX
Quanterix
-7.06%-26.58%-39.96%-28.42%+25.91%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Accelerate Diagnostics, Inc. stock logo
AXDX
Accelerate Diagnostics
4.0621 of 5 stars
3.33.00.04.72.32.50.6
HORIBA, Ltd. stock logo
HRIBF
HORIBA
N/AN/AN/AN/AN/AN/AN/AN/A
Pacific Biosciences of California, Inc. stock logo
PACB
Pacific Biosciences of California
1.6806 of 5 stars
3.31.00.00.02.21.71.3
Quanterix Co. stock logo
QTRX
Quanterix
2.9884 of 5 stars
3.65.00.00.02.92.50.0

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Accelerate Diagnostics, Inc. stock logo
AXDX
Accelerate Diagnostics
2.50
Moderate Buy$1.0035.78% Upside
HORIBA, Ltd. stock logo
HRIBF
HORIBA
N/AN/AN/AN/A
Pacific Biosciences of California, Inc. stock logo
PACB
Pacific Biosciences of California
2.58
Moderate Buy$9.05546.43% Upside
Quanterix Co. stock logo
QTRX
Quanterix
3.17
Buy$32.00103.17% Upside

Current Analyst Ratings

Latest HRIBF, PACB, QTRX, and AXDX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/17/2024
Pacific Biosciences of California, Inc. stock logo
PACB
Pacific Biosciences of California
TD Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$12.00 ➝ $2.50
4/10/2024
Pacific Biosciences of California, Inc. stock logo
PACB
Pacific Biosciences of California
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetEqual Weight ➝ Equal Weight$8.00 ➝ $3.00
4/10/2024
Pacific Biosciences of California, Inc. stock logo
PACB
Pacific Biosciences of California
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$9.00 ➝ $7.00
4/2/2024
Accelerate Diagnostics, Inc. stock logo
AXDX
Accelerate Diagnostics
William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform
4/1/2024
Accelerate Diagnostics, Inc. stock logo
AXDX
Accelerate Diagnostics
Craig Hallum
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetHold ➝ Hold$2.00 ➝ $1.00
3/4/2024
Quanterix Co. stock logo
QTRX
Quanterix
Scotiabank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetSector Outperform ➝ Sector Outperform$30.00 ➝ $32.00
2/16/2024
Pacific Biosciences of California, Inc. stock logo
PACB
Pacific Biosciences of California
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$12.50 ➝ $12.00
2/1/2024
Quanterix Co. stock logo
QTRX
Quanterix
Scotiabank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageSector Outperform$30.00
(Data available from 4/17/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Accelerate Diagnostics, Inc. stock logo
AXDX
Accelerate Diagnostics
$12.06M1.32N/AN/A($1.37) per share-0.54
HORIBA, Ltd. stock logo
HRIBF
HORIBA
$1.97BN/AN/AN/A$43.98 per shareN/A
Pacific Biosciences of California, Inc. stock logo
PACB
Pacific Biosciences of California
$200.52M1.87N/AN/A$2.62 per share0.53
Quanterix Co. stock logo
QTRX
Quanterix
$122.37M4.90N/AN/A$9.17 per share1.72

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Accelerate Diagnostics, Inc. stock logo
AXDX
Accelerate Diagnostics
-$61.62M-$4.89N/AN/AN/A-454.95%N/A-170.54%5/9/2024 (Estimated)
HORIBA, Ltd. stock logo
HRIBF
HORIBA
$272.92M$6.9014.2616.45N/A13.95%13.25%8.11%N/A
Pacific Biosciences of California, Inc. stock logo
PACB
Pacific Biosciences of California
-$306.73M-$1.21N/AN/AN/A-152.97%-40.23%-15.24%5/9/2024 (Confirmed)
Quanterix Co. stock logo
QTRX
Quanterix
-$32.33M-$0.86N/AN/AN/A-26.42%-9.15%-7.56%5/14/2024 (Estimated)

Latest HRIBF, PACB, QTRX, and AXDX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/9/2024N/A
Pacific Biosciences of California, Inc. stock logo
PACB
Pacific Biosciences of California
-$0.26N/A+$0.26N/AN/AN/A  
2/29/2024Q4 2023
Quanterix Co. stock logo
QTRX
Quanterix
-$0.28-$0.33-$0.05-$0.33$27.92 million$31.55 million    
2/15/202412/31/2023
Pacific Biosciences of California, Inc. stock logo
PACB
Pacific Biosciences of California
-$0.29-$0.27+$0.02-$0.23$57.96 million$58.36 million    
2/14/2024Q4 2023
HORIBA, Ltd. stock logo
HRIBF
HORIBA
N/A$2.41+$2.41$2.58N/A$641.02 million

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Accelerate Diagnostics, Inc. stock logo
AXDX
Accelerate Diagnostics
N/AN/AN/AN/AN/A
HORIBA, Ltd. stock logo
HRIBF
HORIBA
N/AN/AN/AN/AN/A
Pacific Biosciences of California, Inc. stock logo
PACB
Pacific Biosciences of California
N/AN/AN/AN/AN/A
Quanterix Co. stock logo
QTRX
Quanterix
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Accelerate Diagnostics, Inc. stock logo
AXDX
Accelerate Diagnostics
N/A
2.03
1.76
HORIBA, Ltd. stock logo
HRIBF
HORIBA
0.20
3.05
2.03
Pacific Biosciences of California, Inc. stock logo
PACB
Pacific Biosciences of California
1.27
7.81
7.21
Quanterix Co. stock logo
QTRX
Quanterix
N/A
9.84
9.26

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Accelerate Diagnostics, Inc. stock logo
AXDX
Accelerate Diagnostics
17.14%
HORIBA, Ltd. stock logo
HRIBF
HORIBA
N/A
Pacific Biosciences of California, Inc. stock logo
PACB
Pacific Biosciences of California
N/A
Quanterix Co. stock logo
QTRX
Quanterix
86.48%

Insider Ownership

CompanyInsider Ownership
Accelerate Diagnostics, Inc. stock logo
AXDX
Accelerate Diagnostics
33.00%
HORIBA, Ltd. stock logo
HRIBF
HORIBA
N/A
Pacific Biosciences of California, Inc. stock logo
PACB
Pacific Biosciences of California
1.40%
Quanterix Co. stock logo
QTRX
Quanterix
8.20%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Accelerate Diagnostics, Inc. stock logo
AXDX
Accelerate Diagnostics
17921.66 million14.52 millionOptionable
HORIBA, Ltd. stock logo
HRIBF
HORIBA
8,432N/AN/ANot Optionable
Pacific Biosciences of California, Inc. stock logo
PACB
Pacific Biosciences of California
796267.95 million264.20 millionOptionable
Quanterix Co. stock logo
QTRX
Quanterix
44138.06 million34.94 millionOptionable

HRIBF, PACB, QTRX, and AXDX Headlines

SourceHeadline
Quanterix Co. (NASDAQ:QTRX) Receives Average Recommendation of "Buy" from BrokeragesQuanterix Co. (NASDAQ:QTRX) Receives Average Recommendation of "Buy" from Brokerages
americanbankingnews.com - April 16 at 4:22 AM
Quanterix (NASDAQ:QTRX)  Shares Down 7.5% Quanterix (NASDAQ:QTRX) Shares Down 7.5%
americanbankingnews.com - April 14 at 6:08 AM
Quanterix Co. (NASDAQ:QTRX) Short Interest Down 18.7% in MarchQuanterix Co. (NASDAQ:QTRX) Short Interest Down 18.7% in March
marketbeat.com - April 13 at 10:37 AM
Quanterix Asserts Tau Patent Claims as AD Testing Market Heats Up, but IP Defensibility a QuestionQuanterix Asserts Tau Patent Claims as AD Testing Market Heats Up, but IP Defensibility a Question
360dx.com - April 10 at 5:22 PM
Kent Lake Capital LLC Cuts Position in Quanterix Co. (NASDAQ:QTRX)Kent Lake Capital LLC Cuts Position in Quanterix Co. (NASDAQ:QTRX)
marketbeat.com - April 6 at 7:36 PM
Quanterix Co. (NASDAQ:QTRX) Director Laurie J. Olson Sells 1,000 SharesQuanterix Co. (NASDAQ:QTRX) Director Laurie J. Olson Sells 1,000 Shares
insidertrades.com - April 3 at 5:00 AM
Laurie J. Olson Sells 1,000 Shares of Quanterix Co. (NASDAQ:QTRX) StockLaurie J. Olson Sells 1,000 Shares of Quanterix Co. (NASDAQ:QTRX) Stock
marketbeat.com - April 2 at 6:51 PM
Quanterix (NASDAQ:QTRX)  Shares Down 7.7% Quanterix (NASDAQ:QTRX) Shares Down 7.7%
marketbeat.com - April 2 at 5:45 PM
Investing in Quanterix (NASDAQ:QTRX) a year ago would have delivered you a 111% gainInvesting in Quanterix (NASDAQ:QTRX) a year ago would have delivered you a 111% gain
finance.yahoo.com - April 1 at 11:13 AM
Quanterix’s Strong IP Position Fuels Buy Rating in Alzheimer’s Diagnostic MarketQuanterix’s Strong IP Position Fuels Buy Rating in Alzheimer’s Diagnostic Market
markets.businessinsider.com - March 27 at 9:23 AM
Analysts Are Bullish on Top Healthcare Stocks: Quanterix (QTRX), Passage Bio (PASG)Analysts Are Bullish on Top Healthcare Stocks: Quanterix (QTRX), Passage Bio (PASG)
markets.businessinsider.com - March 26 at 1:45 PM
Quanterix (NASDAQ:QTRX)  Shares Down 3.6% Quanterix (NASDAQ:QTRX) Shares Down 3.6%
marketbeat.com - March 26 at 12:39 PM
Analysts Are Bullish on Top Healthcare Stocks: Annovis Bio (ANVS), AbSci (ABSI)Analysts Are Bullish on Top Healthcare Stocks: Annovis Bio (ANVS), AbSci (ABSI)
markets.businessinsider.com - March 22 at 1:33 AM
Quanterix Outlines Partner Path With Labs to Expedite Building Global Alzheimer’s Disease Testing InfrastructureQuanterix Outlines Partner Path With Labs to Expedite Building Global Alzheimer’s Disease Testing Infrastructure
finance.yahoo.com - March 21 at 8:32 PM
Quanterix Outlines Partner Path With Labs to Expedite Building Global Alzheimers Disease Testing InfrastructureQuanterix Outlines Partner Path With Labs to Expedite Building Global Alzheimer's Disease Testing Infrastructure
businesswire.com - March 21 at 5:30 PM
QTRX Apr 2024 22.500 callQTRX Apr 2024 22.500 call
finance.yahoo.com - March 16 at 8:29 AM
QTRX Apr 2024 27.500 putQTRX Apr 2024 27.500 put
finance.yahoo.com - March 16 at 8:29 AM
CryoPort Q4 2023 Earnings PreviewCryoPort Q4 2023 Earnings Preview
msn.com - March 11 at 6:58 PM
Quanterix’s Growth Catalysts: FDA Breakthrough Designation and Alzheimer’s Diagnostic PotentialQuanterix’s Growth Catalysts: FDA Breakthrough Designation and Alzheimer’s Diagnostic Potential
markets.businessinsider.com - March 7 at 2:35 PM
Quanterix Granted Breakthrough Device Designation from U.S. FDA for Blood-Based p-Tau 217 Test for Alzheimers DiseaseQuanterix Granted Breakthrough Device Designation from U.S. FDA for Blood-Based p-Tau 217 Test for Alzheimer's Disease
stockhouse.com - March 6 at 7:24 PM
Quanterix (QTRX) AD Offering Gets FDAs Breakthrough Device TagQuanterix (QTRX) AD Offering Gets FDA's Breakthrough Device Tag
zacks.com - March 6 at 10:51 AM
Quanterix price target raised by $2 at Scotiabank, heres whyQuanterix price target raised by $2 at Scotiabank, here's why
realmoney.thestreet.com - March 4 at 2:16 PM
Quanterix Granted Breakthrough Device Designation from U.S. FDA for Blood-Based p-Tau 217 Test for Alzheimer’s DiseaseQuanterix Granted Breakthrough Device Designation from U.S. FDA for Blood-Based p-Tau 217 Test for Alzheimer’s Disease
finance.yahoo.com - March 4 at 9:15 AM
Quanterix Corporation (NASDAQ:QTRX) Just Released Its Annual Results And Analysts Are Updating Their EstimatesQuanterix Corporation (NASDAQ:QTRX) Just Released Its Annual Results And Analysts Are Updating Their Estimates
finance.yahoo.com - March 3 at 2:00 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Accelerate Diagnostics logo

Accelerate Diagnostics

NASDAQ:AXDX
Accelerate Diagnostics, Inc., an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. The company offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms. It also provides the Accelerate PhenoTest, a test kit for the system, which provides identify and antibiotic susceptibility testing results for patients suspected of bacteremia or fungemia, both life-threatening conditions with high morbidity and mortality risk. The company was formerly known as Accelr8 Technology Corporation and changed its name to Accelerate Diagnostics, Inc. in December 2012. The company was incorporated in 1982 and is headquartered in Tucson, Arizona.
HORIBA logo

HORIBA

OTCMKTS:HRIBF
HORIBA, Ltd. manufactures and sells instruments and systems worldwide. The company operates in five segments: Automotive, Environment/Process, Medical, Semiconductor, and Scientific. The Automotive segment offers engine emission measurement devices; in-use vehicle emission measurement devices; on-board emission measurement devices; in-vehicle exhaust gas measuring devices; driveline test systems; engine test systems; brake test systems; fuel cell test devices; battery test devices; and vehicle development engineering and test engineering services, as well as leases and manages research and development facilities. The Environment/Process segment provides flue gas analyzers, water quality measuring devices, air pollution monitoring analyzers, environmental radiation measuring instruments, and process measurement equipment. The Medical segment offers hematology and CRP, immunology, clinical chemistry, and blood glucose analyzers, blood cell counters, biochemical testing devices, blood glucose testing devices, as well as coagulation/hemostasis analyzers. The Semiconductor segment provides mass flow controllers, chemical concentration monitors, semiconductor contaminant inspection equipment, and residual gas analyzer. The Scientific segment offers Raman spectrometers, pH meters, water quality measuring devices, particle size distribution measuring devices, X -ray fluorescence analyzers, elemental analyzers, fluorescence spectroscopy/lifetime measurement devices, spectrometer/detectors, and gratings. It also engages in the fund management, software development, and automation software for engine. The company's products are used in arts, entertainment, and recreation; education, research and development, and government institution; food and beverage; energy and environment; health care; industrials; information technology; water; materials; mobility and transport; and waste management applications. HORIBA, Ltd. was founded in 1945 and is headquartered in Kyoto, Japan.
Pacific Biosciences of California logo

Pacific Biosciences of California

NASDAQ:PACB
Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing solution to resolve genetically complex problems. The company provides sequencing systems; consumable products, including single molecule real-time (SMRT) technology; long-red sequencing; and various reagent kits designed for specific workflow, such as preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases. It also offers binding kits, such as modified DNA polymerase used to bind SMRTbell libraries to the polymerase in preparation for sequencing; and sequencing kits comprise reagents required for on-instrument, real-time sequencing, including the phospholinked nucleotides. In addition, it provides revio system + sequel systems which conduct, monitor, and analyze single-molecule biochemical reactions in real time; SBB short-read sequencing; onso instrument conducts, monitors, and analyzes SBB biochemical reactions; and SBB consumable, including flow cells, clustering, and sequencing reagent kits. The company serves academic and governmental research institutions; commercial testing and service laboratories; genome centers; public health labs, hospitals and clinical research institutes, and contract research organizations; pharmaceutical companies; and agricultural companies. It markets its products through a sales force and distribution partners in Asia, Australia, Europe, the Middle East, Africa, and Latin America. It has a development and commercialization agreement with Invitae Corporation; and a collaboration with Radboud University Medical to explore genetic causes of rare and genetic diseases. The company was formerly known as Nanofluidics, Inc. and changed its name to Pacific Biosciences of California, Inc. in 2005. Pacific Biosciences of California, Inc. was incorporated in 2000 and is headquartered in Menlo Park, California.
Quanterix logo

Quanterix

NASDAQ:QTRX
Quanterix Corporation, a life sciences company, engages in development and marketing of digital immunoassay platforms that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company offers HD-X instrument, a protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection in an expanded range of applications. It also provides SP-X instrument that is based on Simoa planar array technology for the measurement of multiplex chemiluminescent immunoassays. The company's products include assays include all components required to run enzyme-based immunoassay, such as beads, capture and detector reagents, and enzyme reagents and substrate; and replacement parts, reagents, and antibodies. In addition, it offers contract research services, including sample testing, homebrew assay development, custom assay development, lucent diagnostic, and LDT testing services. The company primarily operates in the areas of neurology, oncology, cardiology, infectious diseases, and inflammation. It sells its products for the life science research sector primarily to laboratories associated with academic and governmental research institutions, as well as pharmaceutical, biotechnology, and contract research companies through a direct field sale, support organizations, and distributors or sales agents. The company was formerly known as Digital Genomics, Inc. and changed its name to Quanterix Corporation in August 2007. Quanterix Corporation was incorporated in 2007 and is headquartered in Billerica, Massachusetts.